Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases
David Cheng, Bharati D. Kochar, Tianxi Cai, Ashwin N. Ananthakrishnan
Topics & Concepts
MedicineTofacitinibUstekinumabInflammatory bowel diseaseInflammatory Bowel DiseasesTumor necrosis factor alphaInternal medicineGastroenterologyUlcerative colitisTumor necrosis factor αVedolizumabTumor necrosis factorsInfliximabPouchitisCrohn's diseaseImmunologyAdalimumabRisk factorColorectal cancerMonoclonalInterleukin 23Inflammatory Bowel DiseaseSpondyloarthritis Studies and TreatmentsRheumatoid Arthritis Research and Therapies